This could be due to various reasons – foremost, the alterations in the methylation of DNA have been seen prominent in AML-MR and MDS, rather than in de novo AML and normal CD34+ cells [42]; further, the expression of TET2 progressively decreases with the increase in severity of de novo AML, [43] but such a risk-stratification was not performed in the de novo AML patients in the current study. The gene discussed is CD34; the disease is acute myeloid leukemia.